Showing results (31-40 of 57) with videos related to
Sort By:
Pageof 6
Leukemia Research|December 3, 2019
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trialElias Jabbour, Nicola Gökbuget, Anjali Advani, et al.Blood|February 25, 2011
CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemiaHideki Makishima, Anna M Jankowska, Michael A McDevitt, et al.British Journal of Haematology|February 1, 2020
Distinctive and common features of moderate aplastic anaemiaBhumika J Patel, Shimoli V Barot, Teodora Kuzmanovic, et al.The Lancet. Oncology|February 24, 2012
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.American Journal of Hematology|July 31, 2018
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimensStuart E Siegel, Anjali Advani, Nita Seibel, et al.JAMA Oncology|February 17, 2018
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A ReviewStuart E Siegel, Wendy Stock, Rebecca H Johnson, et al.Haematologica|September 3, 2016
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemiaNicola Gökbuget, Hervè Dombret, Jose-Maria Ribera, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximabLuis Fayad, Fritz Offner, Mitchell R Smith, et al.Leukemia & Lymphoma|April 9, 2020
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromesGuillermo Garcia-Manero, Naveen Pemmaraju, Yesid Alvarado, et al.Clinical Lymphoma, Myeloma & Leukemia|April 16, 2020
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab OzogamicinTalha Badar, Aniko Szabo, Martha Wadleigh, et al.Pageof 6